Please login to the form below

Not currently logged in
Email:
Password:

Lilly launches innovation platform

Eli Lilly & Company has launched a drug discovery platform that aims to help boost the pharmaceutical company's R&D partnerships through a unique website

Eli Lilly & Company has launched a drug discovery platform focusing on developing treatments in areas of unmet medical need.

The platform is supported by the website openinnovation.Lilly.com through which scientists can submit molecules for Lilly to test to evaluate for further development. Data reports are then provided for them.

In the case of cancer, endocrine, cardiovascular and neuroscience screenings, Lilly said it would retain first rights to negotiate an agreement with the submitter in return for providing the data.

The platform itself consists of three components, the first of which screens submitted molecules for their potential to interact with known disease targets.

The second component then screens the molecules again in order to identify potential new medicines acting by novel mechanisms or pathways.

The final component screens molecules specifically for their potential as therapies for MDR-TB - a form of tuberculosis (TB) that is resistant to some TB medicines.

Dr Jan Lundberg, executive vice president, science and technology, and president, Lilly Research Laboratories, explained that partnership programmes were an increasing priority for Lilly in developing new products.

He said: "We recognise that there are many untapped sources of ideas and molecules outside of Lilly that would otherwise go unnoticed without initiatives like this one that advance science."

27th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics